- Home
- INVA vs BDJ Comparison
INVA vs BDJ Comparison
Compare INVA & BDJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$22.42
Company Overview
Basic Information| Metric | INVA | BDJ |
|---|---|---|
| Founded | 1996 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | INVA | BDJ |
|---|---|---|
| Price | $22.42 | $9.17 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.80 | N/A |
| AVG Volume (30 Days) | ★ 584.5K | 490.9K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.85% |
| EPS Growth | ★ 816.67 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $217,217,000.00 | N/A |
| Revenue This Year | $8.95 | N/A |
| Revenue Next Year | $12.65 | N/A |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | ★ 62.63 | N/A |
| 52 Week Low | $16.52 | $8.42 |
| 52 Week High | $25.15 | $9.76 |
Technical Indicators
Market Signals| Indicator | INVA | BDJ |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 54.90 |
| Support Level | $21.91 | $8.95 |
| Resistance Level | $22.76 | $9.23 |
| Average True Range (ATR) | 0.74 | 0.12 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 38.66 | 58.09 |
Price Performance
Historical Comparison INVA
BDJ
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About BDJ Blackrock Enhanced Equity Dividend Trust
BlackRock Enhanced Equity Dividend Trust is a United States closed-end management investment company. Its investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation.